miR-139-5p Was Identified as Biomarker of Different Molecular Subtypes of Breast Carcinoma

Sun, Hai; Dai, Jing; Chen, Mengze; Chen, Qi; Xie, Qiong; Zhang, Weijun; Li, Guoqing; Yan, Meidi

doi:10.3389/fonc.2022.857714

Cited by 10 publications

(5 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrary to our results, miR-139-5p had previously found downregulated in BC [ 22 , 44 ]. We have found no other article in agreement with our results and have no explanation for this disagreement.…”

Section: Discussioncontrasting

confidence: 99%

Circulating miRNAs signature on breast cancer: the MCC-Spain project

Gómez-Acebo,

Llorca,

Alonso-Molero

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Purpose To build models combining circulating microRNAs (miRNAs) able to identify women with breast cancer as well as different types of breast cancer, when comparing with controls without breast cancer. Method miRNAs analysis was performed in two phases: screening phase, with a total n = 40 (10 controls and 30 BC cases) analyzed by Next Generation Sequencing, and validation phase, which included 131 controls and 269 cases. For this second phase, the miRNAs were selected combining the screening phase results and a revision of the literature. They were quantified using RT-PCR. Models were built using logistic regression with LASSO penalization. Results The model for all cases included seven miRNAs (miR-423-3p, miR-139-5p, miR-324-5p, miR-1299, miR-101-3p, miR-186-5p and miR-29a-3p); which had an area under the ROC curve of 0.73. The model for cases diagnosed via screening only took in one miRNA (miR-101-3p); the area under the ROC curve was 0.63. The model for disease-free cases in the follow-up had five miRNAs (miR-101-3p, miR-186-5p, miR-423-3p, miR-142-3p and miR-1299) and the area under the ROC curve was 0.73. Finally, the model for cases with active disease in the follow-up contained six miRNAs (miR-101-3p, miR-423-3p, miR-139-5p, miR-1307-3p, miR-331-3p and miR-21-3p) and its area under the ROC curve was 0.82. Conclusion We present four models involving eleven miRNAs to differentiate healthy controls from different types of BC cases. Our models scarcely overlap with those previously reported.

show abstract

Section: Discussioncontrasting

confidence: 99%

Circulating miRNAs signature on breast cancer: the MCC-Spain project

Gómez-Acebo,

Llorca,

Alonso-Molero

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

show abstract

“…The guide strand derived from precursor-miR-139 is miR-139-5p, on which many studies have been conducted [23,24]. In cancer research, the downregulation of miR-139-5p has been reported in most cancer types (e.g., breast, gastric, colorectal, bladder, and head and neck cancers, among others) [25][26][27][28][29]. In contrast, a high expression of miR-139-5p has been reported in cancer tissues compared with normal tissues in gastrointestinal stromal tumors [23,30].…”

Section: Discussionmentioning

confidence: 99%

Identification of Tumor-Suppressive miR-139-3p-Regulated Genes: TRIP13 as a Therapeutic Target in Lung Adenocarcinoma

Hagihara,

Tomioka,

Suetsugu

et al. 2023

Cancers

View full text Add to dashboard Cite

Analyses of our microRNA (miRNA) expression signature combined with The Cancer Genome Atlas (TCGA) data revealed that both strands of pre-miR-139 (miR-139-5p, the guide strand, and miR-139-3p, the passenger strand) are significantly downregulated in lung adenocarcinoma (LUAD) clinical specimens. Functional analyses of LUAD cells ectopically expressing miR-139-3p showed significant suppression of their aggressiveness (e.g., cancer cell proliferation, migration, and invasion). The involvement of the passenger strand, miR-139-3p, in LUAD pathogenesis, is an interesting finding contributing to the elucidation of unknown molecular networks in LUAD. Of 1108 genes identified as miR-139-3p targets in LUAD cells, 21 were significantly upregulated in LUAD tissues according to TCGA analysis, and their high expression negatively affected the prognosis of LUAD patients. We focused on thyroid hormone receptor interactor 13 (TRIP13) and investigated its cancer-promoting functions in LUAD cells. Luciferase assays showed that miR-139-3p directly regulated TRIP13. siRNA-mediated TRIP13 knockdown and TRIP13 inhibition by a specific inhibitor (DCZ0415) attenuated the malignant transformation of LUAD cells. Interestingly, when used in combination with anticancer drugs (cisplatin and carboplatin), DCZ0415 exerted synergistic effects on cell proliferation suppression. Identifying the molecular pathways regulated by tumor-suppressive miRNAs (including passenger strands) may aid in the discovery of diagnostic markers and therapeutic targets for LUAD.

show abstract

“…Interestingly, it has been demonstrated that human bone marrow mesenchymal stem cells are able to inhibit BC cells’ growth through the release of exosome cargo with miR-139-5p [ 98 ].…”

Section: The C-mirnas Shared Among the Selected Studiesmentioning

confidence: 99%

Circulating microRNAs in Cancer: A 5-Year Update with a Focus on Breast and Lung Cancers

Siniscalco,

Galderisi,

Peluso

et al. 2024

IJMS

View full text Add to dashboard Cite

Circulating microRNAs (c-miRNAs) are non-coding RNAs found in different bodily fluids and are highly investigated for their prognostic potential and biological role in cancer. In this narrative review, we provide an update of the last five years’ published papers (2018–2023) on PubMed about c-miRNAs in cancer research. We aim to capture the latest research interests in terms of the highly studied cancers and the insights about c-miRNAs. Our analysis revealed that more than 150 papers focusing on c-miRNAs and cancer were published in the last five years. Among these, there was a high prevalence of papers on breast cancer (BC) and lung cancer (LC), which are estimated to be the most diagnosed cancers globally. Thus, we focus on the main evidence and research trends about c-miRNAs in BC and LC. We report evidence of the effectiveness of c-miRNAs in hot topics of cancer research, such as, early detection, therapeutic resistance, recurrence risk and novel detection platform approaches. Moreover, we look at the deregulated c-miRNAs shared among BC and LC papers, focusing on miR-21 and miR-145. Overall, these data clearly indicate that the role of c-miRNAs in cancer is still a hot topic for oncologic research and that blood is the most investigated matrix.

show abstract

miR-139-5p Was Identified as Biomarker of Different Molecular Subtypes of Breast Carcinoma

Cited by 10 publications

References 47 publications

Circulating miRNAs signature on breast cancer: the MCC-Spain project

Circulating miRNAs signature on breast cancer: the MCC-Spain project

Identification of Tumor-Suppressive miR-139-3p-Regulated Genes: TRIP13 as a Therapeutic Target in Lung Adenocarcinoma

Circulating microRNAs in Cancer: A 5-Year Update with a Focus on Breast and Lung Cancers

Contact Info

Product

Resources

About